RenovoRx, Inc. (RNXT) stock
RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30163% above fair value
$1.16−0.06 (-4.92%)
Close on Nov 12, 2026Market cap $52.35MP/E –Yield –
RenovoRx gross margin
Gross margin is gross profit as a percentage of revenue.
RenovoRx's gross margin for the twelve months ending Sep 30, 2026 was 84.0%. For fiscal 2025 it was 70.9%, against 100.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 70.9% | −29.1 |
| FY2024 | Dec 31, 2024 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 82.4% | +2.3 |
| Q2 FY2026 | Jun 30, 2026 | 84.3% | +20.3 |
| Q1 FY2026 | Mar 31, 2026 | 85.1% | +32.8 |
| Q4 FY2025 | Dec 31, 2025 | 88.2% | – |
| Q3 FY2025 | Sep 30, 2025 | 80.1% | – |
| Q2 FY2025 | Jun 30, 2025 | 64.0% | – |
| Q1 FY2025 | Mar 31, 2025 | 52.3% | – |
See a number that looks wrong?